Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Atezolizumab/bevacizumab

Bleeding and immune-related adverse events

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Brown TJ, et al. Evaluating the safety and efficacy of the addition of liver radiation (RT) to atezolizumab and bevacizumab (A/B) in advanced hepatocellular carcinoma (HCC): A retrospective cohort analysis. Journal of Clinical Oncology 42 (Suppl.): No. 3, Jan 2024. Available from: URL: https://ascopubs.org/toc/jco/42/3 [abstract] Brown TJ, et al. Evaluating the safety and efficacy of the addition of liver radiation (RT) to atezolizumab and bevacizumab (A/B) in advanced hepatocellular carcinoma (HCC): A retrospective cohort analysis. Journal of Clinical Oncology 42 (Suppl.): No. 3, Jan 2024. Available from: URL: https://​ascopubs.​org/​toc/​jco/​42/​3 [abstract]
Metadaten
Titel
Atezolizumab/bevacizumab
Bleeding and immune-related adverse events
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-53928-x

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Allopurinol

Case report

Carfilzomib

Case report

Multiple drugs